Longitudinal Albumin–Bilirubin Trajectory and Survival During Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 14.11.2026. Verfasst von Alireza Tojjari und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology & Medical Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Bilirubin, Immune Checkpoint Inhibitors. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aims The albumin–bilirubin (ALBI) score measures hepatic reserve in hepatocellular carcinoma (HCC). We evaluated the association between longitudinal ALBI changes during immune checkpoint inhibitor (ICI) therapy and overall survival (OS), including their prognostic contribution beyond baseline ALBI.
Methods
This retrospective cohort included 227 patients receiving ICI‐based therapy. Serial ALBI trajectory was assessable in 217 patients. Cox regression, patient‐clustered time‐dependent analyses, 42‐, 84‐, and 168‐day landmarks, and endpoint sensitivity analyses were performed.
Results
Of 227 patients, 217 met the serial‐ALBI criteria (149 deaths in the primary analysis). Non‐Decliner, Slow Decliner, and Rapid Decliner groups numbered 98, 61, and 58; median OS was 24.8, 11.5, and 4.8 months. Rapid Decliner versus Non‐Decliner adjusted hazard ratio (HR) was 4.21 (95% confidence interval [CI] 2.70–6.57) and 4.71 (2.98–7.44) after baseline ALBI adjustment. At day 84 ( n = 185; 123 events), adjusted HR was 2.44 (1.51–3.92). Apparent C‐index increased from 0.601 to 0.643 (approximately 0.04); this modest in‐sample gain was not validated.
Conclusions
Worsening longitudinal ALBI was associated with shorter survival in this retrospective HCC cohort, with attenuation in later landmark analyses. The exploratory 180‐day trajectory groups are defined after treatment begins; their Cox HRs summarize associations over follow‐up rather than constant relative hazards. Continuous‐slope estimates were sensitive to extreme observations. Prospective short‐window derivation and independent validation are required before clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology & Medical Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Internal Medicine, Maimonides Medical Center, Brooklyn, New York, USA.
- Department of Hematology and Medical Oncology, West Virginia University Cancer Institute, Morgantown, West Virginia, USA.
- Department of Surgery, Division of Hepatobiliary Surgery, UPMC, Pittsburgh, Pennsylvania, USA.
- Center for Interventional Radiology, Department of Radiology, UPMC, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Alireza Tojjari, Yassine Alami Idrissi, Monica Malhotra, Stela Celaj, Anwaar Saeed
Zitieren
APA
Tojjari, A., Idrissi, Y. A., Shi, Y., Singh, M., Rhee, J., Malhotra, M., Geller, D., Sarwar, A., Celaj, S., Biggins, S. W., & Saeed, A. (2026). Longitudinal Albumin–Bilirubin Trajectory and Survival During Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72506
Vancouver
Tojjari A, Idrissi YA, Shi Y, Singh M, Rhee J, Malhotra M, et al. Longitudinal Albumin–Bilirubin Trajectory and Survival During Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72506
BibTeX
@article{Tojjari2026,
author = {Tojjari, Alireza and Idrissi, Yassine Alami and Shi, Yuming and Singh, Meghana and Rhee, John and Malhotra, Monica and Geller, David and Sarwar, Ammar and Celaj, Stela and Biggins, Scott W and Saeed, Anwaar},
title = {Longitudinal Albumin–Bilirubin Trajectory and Survival During Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cam4.72506}
}
EUVIMED